Somewhat Positive News Coverage Somewhat Unlikely to Affect Kura Oncology (KURA) Stock Price
News articles about Kura Oncology (NASDAQ:KURA) have been trending somewhat positive this week, Accern reports. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kura Oncology earned a news sentiment score of 0.23 on Accern’s scale. Accern also assigned media stories about the company an impact score of 46.1829562519695 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Array Biopharma Inc : Today’s Research Reports on Stocks to Watch: Array BioPharma and Kura Oncology (4-traders.com)
- Kura Oncology, Inc. (KURA) Research Coverage Started at Cowen and Company (americanbankingnews.com)
- Kura Oncology shares double after successful results from phase II trial of lead candidate (proactiveinvestors.co.uk)
- Kura Oncology Inc. (KURA) Is Up Sharply On Phase 2 Study Results (nasdaq.com)
- Kura Oncology, Inc. (KURA) Raised to “Hold” at ValuEngine (americanbankingnews.com)
Kura Oncology (NASDAQ KURA) opened at 11.10 on Wednesday. Kura Oncology has a 52 week low of $4.00 and a 52 week high of $13.80. The stock’s market capitalization is $221.87 million. The firm has a 50 day moving average price of $8.04 and a 200 day moving average price of $8.77.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Monday, August 7th. The company reported ($0.40) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.03. Equities research analysts predict that Kura Oncology will post ($1.53) earnings per share for the current year.
KURA has been the topic of several research analyst reports. Zacks Investment Research raised Kura Oncology from a “hold” rating to a “buy” rating and set a $10.00 price target on the stock in a research report on Thursday, May 18th. Oppenheimer Holdings, Inc. set a $16.00 price target on Kura Oncology and gave the stock a “buy” rating in a research report on Wednesday, June 14th. Citigroup Inc. set a $13.00 price target on Kura Oncology and gave the stock a “buy” rating in a research report on Tuesday, August 8th. Leerink Swann reiterated an “outperform” rating and issued a $18.00 target price (up from $16.00) on shares of Kura Oncology in a research note on Thursday, August 10th. Finally, ValuEngine downgraded Kura Oncology from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $14.15.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Stock Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related stocks with our FREE daily email newsletter.